Cancer chemotherapy and pharmacology

(ISSN: 0344-5704, 1432-0843)

Table of Contents

2013 - 71 (6)

  • Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. 
  • Differing effects of adjuvant chemotherapy according to BRCA1 nuclear expression in gastric cancer. 
  • Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors. 
  • Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies. 
  • A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer. 
  • A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer. 
  • Potential drug-drug interactions at a referral hematology-oncology ward in Iran: a cross-sectional study. 
  • Treatment of malignant ascites with a combination of chemotherapy drugs and intraperitoneal perfusion of verapamil. 
  • Evaluation of the relationship between cetuximab therapy and corrected QT interval changes in patients with advanced malignancies from solid tumors. 
  • Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo. 
  • Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer. 
  • Switching to a low-fat diet attenuates the intensified doxorubicin cardiotoxicity associated with high-fat feeding. 
  • Bevacizumab and central nervous system (CNS) hemorrhage. 
  • Pharmacokinetics and metabolism of SL-01, a prodrug of gemcitabine, in rats. 
  • Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia. 
  • The elimination of MTC-220, a novel anti-tumor agent of conjugate of paclitaxel and muramyl dipeptide analogue, in rats. 
  • Phase II trial of neoadjuvant docetaxel and cisplatin followed by intensity-modulated radiotherapy with concurrent cisplatin in locally advanced nasopharyngeal carcinoma. 
  • Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma. 
  • Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy. 
  • Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer. 
  • A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer. 
  • A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients. 
  • Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer. 
  • Efficacy and safety of ixabepilone in taxane-resistant patients with metastatic breast cancer previously treated with anthracyclines: results of a phase II study in Japan. 
  • Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases. 
  • Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer. 
  • Phase II study of pemetrexed as first-line treatment in elderly (���75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901. 
  • Taxane-sensitivity of ovarian carcinomas previously treated with paclitaxel and carboplatin. 
  • PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. 
  • Anti-tumor action of trichosanthin, a type 1 ribosome-inactivating protein, employed in traditional Chinese medicine: a mini review. 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.